Platelet-released growth factors inhibit proliferation of primary keratinocytes in vitro

Publication date: Available online 18 September 2017
Source:Annals of Anatomy - Anatomischer Anzeiger
Author(s): Andreas Bayer, Mersedeh Tohidnezhad, Rouven Berndt, Sebastian Lippross, Peter Behrendt, Tim Klüter, Thomas Pufe, Holger Jahr, Jochen Cremer, Franziska Rademacher, Maren Simanski, Regine Gläser, Jürgen Harder
Autologous thrombocyte concentrate lysates as platelet-released growth factors (PRGF) or Vivostat Platelet Rich Fibrin (PRF^®) represent important tools in modern wound therapy, especially in the treatment of chronic, hard-to-heal or infected wounds.Nevertheless, underlying cellular and molecular mechanisms of the beneficial clinical effects of a local wound therapy with autologous thrombocyte concentrate lysates are poorly understood. Recently, we have demonstrated that PRGF induces antimicrobial peptides in primary keratinocytes and accelerates keratinocytes' differentiation. In the present study we analyzed the influence of PRGF on primary human keratinocytes' proliferation.Using the molecular proliferation marker Ki-67 we observed a concentration- and time dependent inhibition of Ki-67 gene expression in PRGF treated primary keratinocytes. These effects were independent from the EGFR- and the IL-6-R pathway. Inhibition of primary keratinocytes' proliferation by PRGF treatment was confirmed in colorimetric cell proliferation assays.Together, these data indicate that the clinically observed positive effects of autologous thrombocytes concentrates in the treatment of chronic, hard-to-heal wounds are not based on an increased keratinocytes proliferation.



http://ift.tt/2xitfpB